Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1999 Mar-Jun;72(2-3):211–218.

Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.

E J Kuipers 1, E C Klinkenberg-Knol 1, S G Meuwissen 1
PMCID: PMC2579004  PMID: 10780583

Abstract

Proton pump inhibitors have become of pivotal importance for the treatment of GERD. The purpose of this paper is to review the interaction between Helicobacter pylori and PPIs in the treatment of GERD. H. pylori exaggerates the acid suppressive effects of PPIs. During treatment with these drugs, H. pylori-positive subjects thus have a higher intragastric pH than H. pylori-negative subjects. The mechanism for this phenomenon remains to be elucidated. We hypothesize that it is related to H. pylori-induced corpus gastritis, which impairs parietal cell function. The available evidence suggests that this phenomenon has no clinical relevance for the treatment of GERD. The 24-hr esophageal pH during PPI treatment does not depend on the H. pylori status, nor does the medication dose needed for maintenance therapy or the number of clinical relapses during such therapy depend on the H. pylori status. PPIs, on the other hand, also affect H. pylori. During treatment with these drugs, the pattern of bacterial colonization and associated gastritis shifts proximally. The increased gastritis of the body mucosa is associated with a more rapid development of atrophic gastritis, a condition characterized by a loss of gastric glands and associated with an increased cancer risk. For these reasons, one has to consider H. pylori eradication in infected GERD patients in need of PPI maintenance therapy.

Full text

PDF
211

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berstad A. E., Hatlebakk J. G., Maartmann-Moe H., Berstad A., Brandtzaeg P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut. 1997 Dec;41(6):740–747. doi: 10.1136/gut.41.6.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Correa P., Haenszel W., Cuello C., Zavala D., Fontham E., Zarama G., Tannenbaum S., Collazos T., Ruiz B. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990 Aug 1;50(15):4737–4740. [PubMed] [Google Scholar]
  3. Dixon M. F., Genta R. M., Yardley J. H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996 Oct;20(10):1161–1181. doi: 10.1097/00000478-199610000-00001. [DOI] [PubMed] [Google Scholar]
  4. Ectors N., Dixon M. F. The prognostic value of sulphomucin positive intestinal metaplasia in the development of gastric cancer. Histopathology. 1986 Dec;10(12):1271–1277. doi: 10.1111/j.1365-2559.1986.tb02570.x. [DOI] [PubMed] [Google Scholar]
  5. Eissele R., Brunner G., Simon B., Solcia E., Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology. 1997 Mar;112(3):707–717. doi: 10.1053/gast.1997.v112.pm9041231. [DOI] [PubMed] [Google Scholar]
  6. Filipe M. I., Muñoz N., Matko I., Kato I., Pompe-Kirn V., Jutersek A., Teuchmann S., Benz M., Prijon T. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer. 1994 May 1;57(3):324–329. doi: 10.1002/ijc.2910570306. [DOI] [PubMed] [Google Scholar]
  7. Jönsson K. A., Ström M., Bodemar G., Norrby K. Histologic changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in patients with juxtapyloric ulcer disease. Scand J Gastroenterol. 1988 May;23(4):433–441. doi: 10.3109/00365528809093891. [DOI] [PubMed] [Google Scholar]
  8. Kuipers E. J., Lee A., Klinkenberg-Knol E. C., Meuwissen S. G. Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther. 1995 Aug;9(4):331–340. doi: 10.1111/j.1365-2036.1995.tb00391.x. [DOI] [PubMed] [Google Scholar]
  9. Kuipers E. J., Lundell L., Klinkenberg-Knol E. C., Havu N., Festen H. P., Liedman B., Lamers C. B., Jansen J. B., Dalenback J., Snel P. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996 Apr 18;334(16):1018–1022. doi: 10.1056/NEJM199604183341603. [DOI] [PubMed] [Google Scholar]
  10. Kuipers E. J., Uyterlinde A. M., Peña A. S., Hazenberg H. J., Bloemena E., Lindeman J., Klinkenberg-Knol E. C., Meuwissen S. G. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995 Sep;90(9):1401–1406. [PubMed] [Google Scholar]
  11. Kuipers E. J., Uyterlinde A. M., Peña A. S., Roosendaal R., Pals G., Nelis G. F., Festen H. P., Meuwissen S. G. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995 Jun 17;345(8964):1525–1528. doi: 10.1016/s0140-6736(95)91084-0. [DOI] [PubMed] [Google Scholar]
  12. Labenz J., Tillenburg B., Peitz U., Börsch G., Idström J. P., Verdú E., Stolte M., Blum A. L. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol. 1997 Apr;92(4):576–581. [PubMed] [Google Scholar]
  13. Labenz J., Tillenburg B., Peitz U., Idström J. P., Verdú E. F., Stolte M., Börsch G., Blum A. L. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology. 1996 Mar;110(3):725–732. doi: 10.1053/gast.1996.v110.pm8608881. [DOI] [PubMed] [Google Scholar]
  14. Labenz J., Tillenburg B., Peitz U., Verdú E., Stolte M., Börsch G., Blum A. L. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut. 1997 Jul;41(1):33–36. doi: 10.1136/gut.41.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lamberts R., Creutzfeldt W., Strüber H. G., Brunner G., Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993 May;104(5):1356–1370. doi: 10.1016/0016-5085(93)90344-c. [DOI] [PubMed] [Google Scholar]
  16. Logan R. P., Walker M. M., Misiewicz J. J., Gummett P. A., Karim Q. N., Baron J. H. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995 Jan;36(1):12–16. doi: 10.1136/gut.36.1.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Maaroos H. I., Salupere V., Uibo R., Kekki M., Sipponen P. Seven-year follow-up study of chronic gastritis in gastric ulcer patients. Scand J Gastroenterol. 1985 Mar;20(2):198–204. doi: 10.3109/00365528509089657. [DOI] [PubMed] [Google Scholar]
  18. Peetsalu A., Maaroos H. I., Sipponen P., Peetsalu M. Long-term effect of vagotomy on gastric mucosa and Helicobacter pylori in duodenal ulcer patients. Scand J Gastroenterol Suppl. 1991;186:77–83. [PubMed] [Google Scholar]
  19. Peters F. T., Kuipers E. J., Ganesh S., Sluiter W. J., Klinkenberg-Knol E. C., Lamers C. B., Kleibeuker J. H. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther. 1999 Jul;13(7):921–926. doi: 10.1046/j.1365-2036.1999.00556.x. [DOI] [PubMed] [Google Scholar]
  20. Schenk B. E., Kuipers E. J., Klinkenberg-Knol E. C., Eskes S. A., Meuwissen S. G. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol. 1999 Apr;94(4):884–887. doi: 10.1111/j.1572-0241.1999.982_e.x. [DOI] [PubMed] [Google Scholar]
  21. Solcia E., Fiocca R., Havu N., Dalväg A., Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion. 1992;51 (Suppl 1):82–92. doi: 10.1159/000200921. [DOI] [PubMed] [Google Scholar]
  22. Verdú E. F., Armstrong D., Fraser R., Viani F., Idström J. P., Cederberg C., Blum A. L. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut. 1995 Apr;36(4):539–543. doi: 10.1136/gut.36.4.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Verdú E. F., Armstrong D., Idström J. P., Labenz J., Stolte M., Dorta G., Börsch G., Blum A. L. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut. 1995 Dec;37(6):743–748. doi: 10.1136/gut.37.6.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Villako K., Kekki M., Maaroos H. I., Sipponen P., Tammur R., Tamm A., Keevallik R. A 12-year follow-up study of chronic gastritis and Helicobacter pylori in a population-based random sample. Scand J Gastroenterol. 1995 Oct;30(10):964–967. doi: 10.3109/00365529509096339. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES